Nissui Pharmaceutical Co., Ltd. produces, sells, imports, and exports culture media and diagnostics for medical institutions, research organizations, and food industries in Japan and internationally. It offers in vitro diagnostics and medical devices; culture media for microbiological testing; products for antimicrobial susceptibility tests, microorganism identification, and immunological tests; and quality control serum, which is used for ensuring the accuracy of clinical diagnoses. In addition,, the company provides microbiological testing products for food poisoning detection; immunosorbent assays for the detection of allergies to food items, such as eggs, wheat, milk, shrimp, crabs, buckwheat, peanuts, etc.; and culture media and reagents for regenerative medicine. Further, it supplies testing agents and bulk products to diagnostic agent manufacturers; and CompactDry, a dry medium that is used for coliform counting for food manufacturers. The company was formerly known as Nissan Research Institute Co., Ltd. and changed its name to Nissui Pharmaceutical Co., Ltd. in 1962. Nissui Pharmaceutical Co., Ltd. was founded in 1935 and is headquartered in Tokyo, Japan.
Research context
Nissui Pharmaceutical Co., Ltd appears in PyInvesting’s Tokyo Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Nissui Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 1.5% below its 200 day moving average.
From a valuation standpoint, the stock is 97.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.9.
Nissui Pharmaceutical Co., Ltd's total revenue rose by 13.2% to $3B since the same quarter in the previous year.
Its net income has increased by 7.8% to $194M since the same quarter in the previous year.
Based on the above factors, Nissui Pharmaceutical Co., Ltd gets an overall score of 3/5.